Trial Profile
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Exemestane; Prednisolone; Prednisone
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 23 Jun 2017 Planned End Date changed from 1 Dec 2018 to 30 Sep 2018.